A Phase 3 interventional study of Anifrolumab and Placebo in Active Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 175 sites in 24 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-01-13.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Connective Tissue Diseases with a site in United States — 17 open to participants now, 27 under way, 12 of them phase 3. Connective Tissue Diseases · United States.
Among the 95 studies in Connective Tissue Diseases with a site in United States, this one is the 10th largest by enrollment of the 68 interventional ones that give a count, is one of 2 that started in 2016, is one of 20 in phase 3, and was the 55th registered.
192 studies on the registry are indexed under Connective Tissue Diseases; 56 are open to participants now.
Browse Connective Tissue Diseases studies →17 of the 95 studies in Connective Tissue Diseases with a site in United States are open now. Recruiting first, the newest first:
Valley Health System · Sites in United States
Ages 18+
Vericel Corporation · Sites in United States
Ages 17–65
Brigham and Women's Hospital · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
GlaxoSmithKline · Sites in United States, Argentina, Australia and 8 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Connective Tissue Diseases studies recruiting now, 30 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 27 · Phase 3 21 · Phase 4 5
First in 1979; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 559 is above the median of 58 across 132 interventional studies indexed under Connective Tissue Diseases.
Median enrollment 67 across the 68 interventional studies, 180 across the 25 observational. Of the 61 that completed or were terminated, 20 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 95 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 3 studies filed under Connective Tissue Diseases — fewer than ten, so there is no comparison to draw.
6 of the studies in Connective Tissue Diseases with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
| NCT06104228Bastiaan Driehuys129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) | 2027-01-01 |
| NCT02234388Hospital for Special Surgery, New YorkUndifferentiated Connective Tissue Disease Registry | 2027-03-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 95 studies in Connective Tissue Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterise long-term safety and tolerability of intravenous anifrolumab.
This is a Phase 3, multicentre, multinational, randomised, double-blind, placebo-controlled extension study to characterising the long term safety and tolerability of of an intravenous treatment regimen of anifrolumab versus placebo in subjects with moderately to severely active systemic lupus erythematosus who completed a Phase 3 study (D3461C00004 or D3461C00005) through the 52-week double-blind treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Meets the following TB criteria:
Exclusion Criteria:
Receipt of any of the following within the last 60 days:
Receipt of any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anifrolumab
Biological: Anifrolumab
Placebo
Drug: Placebo
Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs)
The event rate per 100 participant years was defined as the number of participants with an event divided by the sum of exposure time during the LTE study (including follow-up) in days for all participants in the analysis set multiplied by 365.25 days/year multiplied by 100. The exposure in a time period for each participant was calculated as end of period - start of period + 1. EAIRs of AESIs are presented as event rate per 100 participant years. The following AESIs were pre-defined: * Non-opportunistic serious infections * Opportunistic infections * Anaphylaxis * Malignancy * Herpes zoster * Tuberculosis (TB) (including latent TB) * Influenza * Vasculitis (non-systemic lupus erythematosus \[SLE\]) * Major cardiovascular events as according to the Cardiovascular Event Adjudication Committee.
Time frame: Up to a maximum of 1114 days
EAIRs of Serious Adverse Events (SAEs)
EAIRs of SAEs are presented as event rate per 100 participant years. An SAE was an AE occurring during any study phase that fulfils 1 or more of the following criteria: * Results in death * Is immediately life-threatening * Requires in-patient hospitalisation or prolongation of existing hospitalisation * Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions * Is a congenital abnormality or birth defect * Is an important medical event that may jeopardise the participant or may require medical intervention to prevent one of the outcomes listed above.
Time frame: Up to a maximum of 1114 days
This long-term extension (LTE) study was conducted at 176 study centres in 24 countries.
| Milestone | Randomised Anifrolumab 300 mg | Placebo Feeder + Placebo LTE | Placebo Feeder + Anifrolumab 300 mg LTE | Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE |
|---|---|---|---|---|
| Started | 257 | 112 | 111 | 67 |
| Completed | 178 | 54 | 69 | 41 |
| Not completed | 79 | 58 | 42 | 26 |
| Withdrew: Adverse event | 11 | 4 | 5 | 8 |
| Withdrew: Condition under investigation improved | 1 | 0 | 0 | 0 |
| Withdrew: Condition under investigation worsened | 0 | 2 | 1 | 0 |
| Withdrew: Death | 2 | 1 | 2 | 0 |
| Withdrew: Development of study-specific withdrawal criteria | 1 | 0 | 0 | 1 |
| Withdrew: Failure to meet randomisation criteria | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 10 | 6 | 3 | 3 |
| Withdrew: Lost to follow-up | 5 | 6 | 3 | 1 |
| Withdrew: Severe non-compliance to protocol | 1 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 38 | 29 | 20 | 12 |
| Withdrew: Missing | 1 | 0 | 0 | 0 |
| Withdrew: Due to covid-19 pandemic | 7 | 2 | 4 | 0 |
| Withdrew: Other - not due to covid-19 pandemic | 2 | 6 | 2 | 1 |
The event rate per 100 participant years was defined as the number of participants with an event divided by the sum of exposure time during the LTE study (including follow-up) in days for all participants in the analysis set multiplied by 365.25 days/year multiplied by 100. The exposure in a time period for each participant was calculated as end of period - start of period + 1. EAIRs of AESIs are presented as event rate per 100 participant years. The following AESIs were pre-defined: * Non-opportunistic serious infections * Opportunistic infections * Anaphylaxis * Malignancy * Herpes zoster * Tuberculosis (TB) (including latent TB) * Influenza * Vasculitis (non-systemic lupus erythematosus \[SLE\]) * Major cardiovascular events as according to the Cardiovascular Event Adjudication Committee.
| Events per 100 participant years | Randomised Anifrolumab 300 mg | Placebo Feeder + Placebo LTE | Placebo Feeder + Anifrolumab 300 mg LTE | Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE |
|---|---|---|---|---|
| Exposure-adjusted Incidence Rates (EAIRs) of Adverse Events of Special Interest (AESIs) | 11.0 | 9.6 | 12.9 | 12.5 |
EAIRs of SAEs are presented as event rate per 100 participant years. An SAE was an AE occurring during any study phase that fulfils 1 or more of the following criteria: * Results in death * Is immediately life-threatening * Requires in-patient hospitalisation or prolongation of existing hospitalisation * Results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions * Is a congenital abnormality or birth defect * Is an important medical event that may jeopardise the participant or may require medical intervention to prevent one of the outcomes listed above.
| Events per 100 participant years | Randomised Anifrolumab 300 mg | Placebo Feeder + Placebo LTE | Placebo Feeder + Anifrolumab 300 mg LTE | Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE |
|---|---|---|---|---|
| EAIRs of Serious Adverse Events (SAEs) | 8.5 | 11.2 | 10.1 | 10.7 |
Collected over Day 1 up to until follow-up visit 2 (Week 164). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomised Anifrolumab 300 mg | 3/257 (1.2%) | 56/257 (21.8%) | 195/257 (75.9%) |
| Placebo Feeder + Placebo LTE | 1/112 (0.9%) | 27/112 (24.1%) | 79/112 (70.5%) |
| Placebo Feeder + Anifrolumab 300 mg LTE | 3/111 (2.7%) | 26/111 (23.4%) | 81/111 (73%) |
| Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE | 2/67 (3%) | 14/67 (20.9%) | 53/67 (79.1%) |
| Event | Randomised Anifrolumab 300 mg | Placebo Feeder + Placebo LTE | Placebo Feeder + Anifrolumab 300 mg LTE | Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE |
|---|---|---|---|---|
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 6/257 | 6/112 | 1/111 | 2/67 |
| PneumoniaInfections and infestations | 6/257 | 2/112 | 3/111 | 3/67 |
| COVID-19 pneumoniaInfections and infestations | 3/201 | 1/64 | 3/82 | 0/42 |
| Herpes zosterInfections and infestations | 6/257 | 1/112 | 3/111 | 1/67 |
| COVID-19Infections and infestations | 4/201 | 0/64 | 2/82 | 0/42 |
| GastroenteritisInfections and infestations | 1/257 | 1/112 | 2/111 | 0/67 |
| BronchitisInfections and infestations | 0/257 | 0/112 | 2/111 | 0/67 |
| Bacterial sepsisInfections and infestations | 0/257 | 0/112 | 0/111 | 1/67 |
| Cellulitis staphylococcalInfections and infestations | 0/257 | 0/112 | 0/111 | 1/67 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/257 | 0/112 | 0/111 | 1/67 |
| Event | Randomised Anifrolumab 300 mg | Placebo Feeder + Placebo LTE | Placebo Feeder + Anifrolumab 300 mg LTE | Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 63/257 | 13/112 | 29/111 | 15/67 |
| BronchitisInfections and infestations | 41/257 | 9/112 | 17/111 | 16/67 |
| Urinary tract infectionInfections and infestations | 57/257 | 16/112 | 18/111 | 9/67 |
| Upper respiratory tract infectionInfections and infestations | 55/257 | 18/112 | 22/111 | 8/67 |
| Herpes zosterInfections and infestations | 16/257 | 6/112 | 12/111 | 10/67 |
| HeadacheNervous system disorders | 28/257 | 11/112 | 7/111 | 10/67 |
| PharyngitisInfections and infestations | 20/257 | 5/112 | 12/111 | 9/67 |
| Back painMusculoskeletal and connective tissue disorders | 18/257 | 10/112 | 12/111 | 9/67 |
| GastroenteritisInfections and infestations | 7/257 | 7/112 | 13/111 | 3/67 |
| InsomniaPsychiatric disorders | 8/257 | 3/112 | 5/111 | 7/67 |
Full Analysis Set (FAS) - LTE Study: consisted of all participants who were randomised and received at least 1 dose of investigational product in the LTE Study.
| Age, Categorical(Participants) | Randomised Anifrolumab 300 mg | Placebo Feeder + Placebo LTE | Placebo Feeder + Anifrolumab 300 mg LTE | Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 247 | 111 | 107 | 65 | 530 |
| >=65 years | 10 | 1 | 4 | 2 | 17 |
| Age, Continuous(Years) | Randomised Anifrolumab 300 mg | Placebo Feeder + Placebo LTE | Placebo Feeder + Anifrolumab 300 mg LTE | Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE | Total |
|---|---|---|---|---|---|
| Mean | 43.4 ± 11.51 | 41.4 ± 11.46 | 42.2 ± 12.24 | 42.4 ± 11.70 | 42.6 ± 11.67 |
| Sex: Female, Male(Participants) | Randomised Anifrolumab 300 mg | Placebo Feeder + Placebo LTE | Placebo Feeder + Anifrolumab 300 mg LTE | Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE | Total |
|---|---|---|---|---|---|
| Female | 237 | 103 | 102 | 63 | 505 |
| Male | 20 | 9 | 9 | 4 | 42 |
| Race/Ethnicity, Customized(Participants) | Randomised Anifrolumab 300 mg | Placebo Feeder + Placebo LTE | Placebo Feeder + Anifrolumab 300 mg LTE | Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE | Total |
|---|---|---|---|---|---|
| White | 173 | 77 | 70 | 45 | 365 |
| Black or African American | 28 | 11 | 17 | 10 | 66 |
| Asian | 33 | 10 | 12 | 6 | 61 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| American Indian or Alaska Native | 3 | 1 | 0 | 0 | 4 |
| Other | 15 | 11 | 10 | 6 | 42 |
| Missing | 5 | 2 | 2 | 0 | 9 |
| Race/Ethnicity, Customized(Participants) | Randomised Anifrolumab 300 mg | Placebo Feeder + Placebo LTE | Placebo Feeder + Anifrolumab 300 mg LTE | Anifrolumab 150 mg Feeder + Anifrolumab 300 mg LTE | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 54 | 28 | 22 | 14 | 118 |
| Not Hispanic or Latino | 198 | 82 | 87 | 53 | 420 |
| Missing | 5 | 2 | 2 | 0 | 9 |
Showing the first 100 of 175 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in Dec 2021, 65 months.
Results were first posted in Jan 2023, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anifrolumab